Pharmacogenetic influences on treatment response and toxicity in colorectal cancer

Benjamin R. Tan, Howard L. McLeod

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Current use of chemotherapeutic and targeted agents for advanced colorectal cancer (CRC) results in high tumor response rates and relatively long overall patient survival. Fluoropyrimidines, irinotecan, and oxaliplatin are highly active in first-line and salvage therapy of colorectal cancer. Targeted therapies, including anti-angiogenesis agents and anti-epidermal growth factor receptor antibodies, have been incorporated with traditional chemotherapy and offer additional options for patients with CRC. However, there is marked variability in response to therapy, as well as frequency and severity of toxicities. Molecular markers and pharmacogenomic profiling may improve prediction of patients who will experience significant benefit or toxicity from currently available agents. Validation of these predictive factors in prospective clinical trials is now necessary to allow for a rational and systematic individualization of cancer therapy.

Original languageEnglish
Pages (from-to)113-119
Number of pages7
JournalSeminars in Oncology
Issue number1 SPEC. ISS.
StatePublished - Feb 2005


Dive into the research topics of 'Pharmacogenetic influences on treatment response and toxicity in colorectal cancer'. Together they form a unique fingerprint.

Cite this